热放化三联疗法治疗非小细胞肺癌的Meta分析

目的系统评价热放化三联疗法治疗非小细胞肺癌的疗效及安全性,为临床实践与更深入研究提供参考。方法计算机检索Cochrane Library、PubMed、EMbase、CBM、CNKI、VIP、WanFang Data,同时辅以其他检索,收集所有比较热放化三联与非三联疗法治疗非小细胞肺癌的随机对照试验(RCT)。各数据库检索时间均从建库至2011年5月1日。参考Cochrane质量评价标准并结合本研究特点对纳入研究进行质量评价后,采用RevMan 5.1软件进行Meta分析。结果共纳入8个RCT,546例患者。Meta分析结果显示:①总有效率:热放化三联疗法的总有效率高于其它非三联疗法,其中三联疗法对比放化、热化及单化的差异有统计学意义,其OR值及其95%CI分别为2.05(1.18,3.56)、3.41(1.12,10.38)和6.11(1.20,31.16)。②在放射性肺炎、放射性食管炎及粒细胞减少的安全性指标方面,热放化三联疗法的发生率均低于放化二联疗法的发生率,但只有粒细胞减少发生率的差异有统计学意义OR=0.34,95%CI(0.19,0.59)]。结论与其它疗法相比,热放化三联疗法治疗非小细胞肺癌有提高疗效和安全性的趋势,但有待更多试验进一步证实;热放化三联疗法有效性和安全性均优于常规的放化二联疗法,但尚缺乏长期疗效和更全面的安全性的相关证据。

HRCT for Non-Small Cell Lung Cancer: A Meta-Analysis

Objective To evaluate the clinical efficacy and safety of hyperthermia combined with radiotherapy and chemotherapy(HRCT) for non-small cell lung cancer(NSCLC),so as to provide references for further clinical practice and research.Methods The databases such as The Cochrane Library,PubMed,EMbase,CBM,CNKI,VIP and WanFang Data were searched on computer from the date of their establishment to May 1st of 2011,and other sources as supplied were also retrieved to collect all the relevant randomized controlled trial...